The health department at the University of Arizona is investigating whether employees of a health facility where a new vaccine was approved last month are using the company’s products improperly.

The company said Thursday that the investigation is ongoing, and that it is working to make the information available to the public. 

The Arizona Republic reported in April that the U.S. Food and Drug Administration had approved a new type of influenza vaccine from GlaxoSmithKline called a “pharmaceutical vaccine.”

That vaccine, approved in July, uses the same combination of antibodies as Glaxos’ flu vaccine and has been approved by the World Health Organization.

It was approved by another agency last month and will be released in the U: the United States and Canada on Nov. 6.

The US Food and Cosmetic Products Safety Commission (FPSC) recommended the use of this vaccine in July as a way to reduce the risk of contracting influenza in the United States.

The FDA has said that using the same vaccine for the first time in the country could increase the risk that the virus will spread to people who are not vaccinated, or to people not vaccinated in the first place. 

Glaxos has been criticized for its use of a vaccine it didn’t approve.

Glaxom has been under fire for the use and lack of oversight of the vaccine used in the US, which Glaxowks said is the only approved vaccine in the world.